Literature DB >> 9181387

Interpretive criteria for susceptibility testing of coagulase-negative staphylococci with special reference to netilmicin.

B Neumeister1, S Kastner, P Bartmann, M Trautmann, R Marre.   

Abstract

Antibiotic susceptibility of 171 isolates of coagulase-negative staphylococci from 66 preterm infants at a neonatal intensive care unit was tested by the microbroth dilution method. Results were interpreted according to DIN as well as according to NCCLS. Because of the bimodal distribution of MIC values within the CNS population tested, results of susceptibility interpretation according to DIN were identical to NCCLS with the exception of netilmicin (NCCLS: 89% susceptibility; DIN: 16% susceptibility). Since netilmicin is frequently used for treatment of infections caused by coagulase-negative staphylococci, this difference may be of clinical significance.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9181387     DOI: 10.1007/BF02113608

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  8 in total

Review 1.  [The aminoglycosides].

Authors:  R Marre; E Schulz; K Sack
Journal:  Internist (Berl)       Date:  1989-01       Impact factor: 0.743

Review 2.  Coagulase-negative staphylococcal infection in the neonate.

Authors:  J W St Geme; M C Harris
Journal:  Clin Perinatol       Date:  1991-06       Impact factor: 3.430

3.  Resistance of gram-negative bacilli and staphylococci from blood cultures to aminoglycoside antibiotics. Comparison of 3 in vitro investigations from Austria 1982-1988.

Authors:  H Mittermayer; M Rotter; G Breitfellner; F Riezinger; W Thiel; L Binder; R Watschinger
Journal:  Zentralbl Bakteriol       Date:  1990-04

4.  Breakpoints in in-vitro antibiotic sensitivity testing. Report by a working party of the British Society for Antimicrobial Chemotherapy.

Authors: 
Journal:  J Antimicrob Chemother       Date:  1988-06       Impact factor: 5.790

5.  Definition and determination of in vitro antibiotic susceptibility breakpoints for bacteria in France. The Comité de l'Antibiogramme de la Société Française de Microbiologie.

Authors:  C J Soussy; R Cluzel; P Courvalin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-03       Impact factor: 3.267

6.  Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration.

Authors:  R D Moore; P S Lietman; C R Smith
Journal:  J Infect Dis       Date:  1987-01       Impact factor: 5.226

7.  Characterization of coagulase-negative staphylococci causing nosocomial infections in preterm infants.

Authors:  B Neumeister; S Kastner; S Conrad; G Klotz; P Bartmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-10       Impact factor: 3.267

8.  Gene homogeneity for aminoglycoside-modifying enzymes in gram-positive cocci.

Authors:  H Ounissi; E Derlot; C Carlier; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

  8 in total
  1 in total

1.  An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial.

Authors:  Louise F Hill; Mark A Turner; Irja Lutsar; Paul T Heath; Pollyanna Hardy; Louise Linsell; Evelyne Jacqz-Aigrain; Emmanuel Roilides; Mike Sharland
Journal:  Trials       Date:  2020-04-15       Impact factor: 2.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.